Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Cell and Gene Therapy Insights 2026; 12(9), 889–910 10.18609/cgti.2026.112 Recombinant adeno-associated virus (rAAV) has emerged as a leading platform for gene therapy, leveraging both naturally occurring and engineered capsids to deliver therapeutic transgenes. As clinical and research demand for rAAV has grown, vector quality and manufacturing consistency have become critical considerations.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
